Nuvectis Pharma, Inc. (NVCT)
USD 4.7
(-8.02%)
USD 4.7
(-8.02%)
| Breakdown | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | - | 149 Thousand | - | - |
| Cost of Revenue | 22.89 Million | 19.23 Million | 12.89 Million | - |
| Gross Profit | -22.89 Million | -19.08 Million | -12.89 Million | - |
| Operating Expenses | 22.89 Million | 19.23 Million | 12.89 Million | 10 Thousand |
| Selling, General and Administrative Expenses | 7.51 Million | 6 Million | 3.34 Million | 10 Thousand |
| Research and Development Expenses | 15.38 Million | 13.22 Million | 9.54 Million | - |
| Other Expenses | - | - | - | - |
| Cost and Expenses | 22.89 Million | 19.23 Million | 12.89 Million | 10 Thousand |
| Operating Income | -22.89 Million | -19.23 Million | -12.89 Million | -10 Thousand |
| Interest Expense | - | 149 Thousand | - | - |
| Income Tax Expense | - | -298 Thousand | -4000.00 | -24.00 |
| Earnings before Tax | -22.26 Million | -19.08 Million | -12.89 Million | -10 Thousand |
| Net Income | -22.26 Million | -18.78 Million | -12.88 Million | -10 Thousand |
| Earnings Per Share Basic | -1.43 | -1.48 | -1.01 | -0.00 |
| Earnings Per Share Diluted | -1.43 | -1.48 | -1.01 | -0.00 |
| Weighted Average Shares Outstanding | 15.55 Million | 12.65 Million | 12.71 Million | 12.71 Million |
| Weighted Average Shares Outstanding (Diluted) | 15.55 Million | 12.65 Million | 12.71 Million | 12.71 Million |
| Gross Margin | - | -128.09 | - | - |
| EBIT Margin | - | -129.09 | - | - |
| Profit Margin | - | -126.09 | - | - |
| EBITDA | -22.89 Million | -19.23 Million | -12.89 Million | - |
| Earnings Before Tax Margin | - | -129.09 | - | - |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | -4.1 Million | - |
| Cost of Revenue | 4.35 Million | 4.64 Million | 4.39 Million | 22.89 Million | 10.96 Million | 6.15 Million |
| Gross Profit | -4.35 Million | -4.64 Million | -4.39 Million | -22.89 Million | -15.06 Million | -6.15 Million |
| Operating Expenses | 4.35 Million | 4.64 Million | 4.39 Million | 22.89 Million | 6.86 Million | 6.15 Million |
| Selling, General and Administrative Expenses | 1.54 Million | 1.7 Million | 1.73 Million | - | 2.6 Million | 1.67 Million |
| Research and Development Expenses | 2.81 Million | 2.94 Million | 2.66 Million | - | 4.26 Million | 4.48 Million |
| Other Expenses | - | - | - | - | - | - |
| Cost and Expenses | 8.71 Million | 4.64 Million | 4.39 Million | 22.89 Million | 6.86 Million | 6.15 Million |
| Operating Income | -8.71 Million | -4.64 Million | -4.39 Million | -22.89 Million | -6.86 Million | -6.15 Million |
| Interest Expense | - | - | - | - | 52 Thousand | - |
| Income Tax Expense | - | - | -43.27 Thousand | 1000.00 | 1000.00 | 6.19 Million |
| Earnings before Tax | -4.15 Million | -4.42 Million | -4.17 Million | -22.26 Million | -6.62 Million | -5.88 Million |
| Net Income | -4.15 Million | -4.42 Million | -4.17 Million | -22.26 Million | -6.62 Million | -5.88 Million |
| Earnings Per Share Basic | -0.24 | -0.26 | -0.25 | - | -0.38 | -0.37 |
| Earnings Per Share Diluted | -0.24 | -0.26 | -0.25 | - | -0.38 | -0.37 |
| Weighted Average Shares Outstanding | 17.23 Million | 16.9 Million | 16.55 Million | 15.55 Million | 17.41 Million | 16.1 Million |
| Weighted Average Shares Outstanding (Diluted) | 17.23 Million | 16.9 Million | 16.55 Million | 15.55 Million | 17.41 Million | 16.1 Million |
| Gross Margin | - | - | - | - | 3.67 | - |
| EBIT Margin | - | - | - | - | 1.67 | - |
| Profit Margin | - | - | - | - | 1.61 | - |
| EBITDA | -8.71 Million | -4.64 Million | -4.39 Million | - | -6.86 Million | -6.15 Million |
| Earnings Before Tax Margin | - | - | - | - | 1.67 | - |
000959
PUCK
PSCO
TRJA
SNA
MEL